Vyant Bio Inc in position to be fully funded through 2023 following sale of vivoPharm subsidiary, 3Q results show
Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at least the...